The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Efficacy and Safety of Pegylated (40–Kd) Interferon α–2A Compared With Interferon α–2A in Noncirrhotic Patients With Chronic Hepatitis C
Abstract
Administration of interferon (IFN) 3 times weekly in patients with chronic hepatitis C (CHC) is associated with low sustained responses, which may be, in part, related to this regimen's inability to maintain IFN concentrations sufficient to suppress viral replication. An enhanced IFN molecule produced by the covalent attachment of a branched 40–kd polyethylene glycol moiety to IFN α–2a (PEG[40kd] IFN α–2a) exhibits sustained absorption, a restricted volume of distribution, and reduced clearance compared with unmodified IFN α–2a. One hundred fifty–nine patients with CHC participated in a randomized, ascending–dose (45 or 90, 180, 270 μg) study comparing PEG(40kd) IFN α–2a administered once weekly with 3 MIU IFN α–2a administered 3 times weekly for 48 weeks to determine the most appropriate PEG(40kd) IFN α–2a dose for subsequent clinical trials. Efficacy was assessed by measuring hepatitis C virus (HCV) RNA following a 24–week treatment–free period. Sustained virological responses for PEG(40kd) IFN α–2a once weekly were 10% (45 μg; not significant), 30% (90 μg; P = .009), 36% (180 μg; P = .0006), and 29% (270 μg; P = .004), compared with 3% for the 3–times–weekly 3–MIU IFN α–2a regimen. The types and frequencies of adverse events and laboratory abnormalities were similar among all groups. In conclusion, once–weekly PEG(40kd) IFN α–2a was associated with a higher number of sustained virological responses compared with IFN α–2a 3 times weekly in patients with CHC, but had a similar safety profile. The 180–μg PEG(40kd) IFN α–2a dose appeared to be the optimal dose based on sustained virological response and its associated side–effect profile.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Histological grading and staging of chronic hepatitis
Ishak, K., Baptista, A., Bianchi, L., Callea, F., De Groote, J., Gudat, F., Denk, H., Desmet, V., Korb, G., MacSween, R. N. M., et al. (1995) · Journal of Hepatology · doi:10.1016/0168-8278(95)80226-6 · Cited by 5,029
McHutchison, J. G., Gordon, S. C., Schiff, E. R., Shiffman, M. L., Lee, W. M., Rustgi, V. K., Goodman, Z. D., Ling, M.-H., Cort, S., & Albrecht, J. K. (1998) · New England Journal of Medicine · doi:10.1056/nejm199811193392101 · Cited by 3,465
Self-citationPoynard, T., Marcellin, P., Lee, S. S., Niederau, C., Minuk, G. S., Ideo, G., Bain, V., Heathcote, J., Zeuzem, S., Trepo, C., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)07124-4 · Cited by 2,318
Hepatitis C Virus Type 1b (II) Infection in France and Italy
Nousbaum, J.-B., Pol, S., Nalpas, B., Landais, P., Berthelot, P., Brechot, C., & and The Collaborative Study Group* (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-3-199502010-00001 · Cited by 489
Factors predictive of a beneficial response to therapy of hepatitis C
Davis, G. L., & Lau, J. Y. (1997) · Hepatology · doi:10.1002/hep.510260721 · Cited by 325
Clinical Pharmacokinetics of Interferons
Wills, R. J. (1990) · Clinical Pharmacokinetics · doi:10.2165/00003088-199019050-00003 · Cited by 247
Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C
Lai, M., Kao, J., Yang, P., Wang, J., Chen, P., Chan, K., Chu, J., & Chen, D. (1996) · Gastroenterology · doi:10.1053/gast.1996.v111.pm8898645 · Cited by 243
Reddy, K. R. (2000) · Annals of Pharmacotherapy · doi:10.1345/aph.10054 · Cited by 157
Cited by
Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection
Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Gonçales, F. L., Häussinger, D., Diago, M., Carosi, G., Dhumeaux, D., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020047 · Cited by 6,389
Self-citationHadziyannis, S. J., Sette, H., Morgan, T. R., Balan, V., Diago, M., Marcellin, P., Ramadori, G., Bodenheimer, H., Bernstein, D., Rizzetto, M., et al. (2004) · Annals of Internal Medicine · doi:10.7326/0003-4819-140-5-200403020-00010 · Cited by 2,836
Self-citationLavanchy, D. (2004) · Journal of Viral Hepatitis · doi:10.1046/j.1365-2893.2003.00487.x · Cited by 2,642
Diagnosis, management, and treatment of hepatitis C†
Strader, D. B., Wright, T., Thomas, D. L., & Seeff, L. B. (2004) · Hepatology · doi:10.1002/hep.20119 · Cited by 1,709
Self-citationPegylation: A Novel Process for Modifying Pharmacokinetics
Harris, J. M., Martin, N. E., & Modi, M. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140070-00005 · Cited by 913
Metadata
- Authors
- Reddy, R. K., Wright, T. L., Pockros, P. J., Shiffman, M., Everson, G., Reindollar, R., Fried, M. W., Purdum, P. P., Jensen, D., Smith, C., Lee, W. M., Boyer, T. D., Lin, A., Pedder, S., & DePamphilis, J.
- Venue
- Hepatology
- Published
- 2001-02
- Volume
- 33
- Issue
- 2
- Pages
- 433-438
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2100227035
- Cited by
- 359
- References
- 8
- FWCI
- 27.60
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.